After 5% Sales Growth In Its FY 2020, P&G Bullish For 2021 Despite Looming Economic Threats
Executive Summary
Macro factors that could hamper results include the economic recession caused by businesses’ reactions to novel coronavirus pandemic, the impact of COVID-19 on consumer buying trends and disruptions to supply chains.
You may also be interested in...
US Q2 Consumer Health Earnings Preview: Will More Favorable Year-Ago Comparisons Help?
April-June sales of OTC drugs, supplements and personal care products likely will show at least notable and potentially strong increases from year-ago period when consumers slowed spending after splurging during 2020 Q1 as novel coronavirus pandemic sent shockwaves through the marketplace.
P&G Boosts Guidance Again Despite Dipping 'Consumption Levels' Expected Through June
On a “strong first half of the base,” P&G increased FY2021 guidance for organic sales growth and core earnings per share despite a “sequential deceleration” in US consumption in its categories in December and so far in January.
P&G Health, Hygiene Brands Ride Consumer ‘Trust’ To Sales Growth Amid Pandemic Uncertainty
“There’s a heightened need for products that deliver against health, hygiene and clean home concerns and a willingness to spend just a little bit more to ensure that I’m using a product that I know and trust,” says CFO Jon Moeller